To improve the management of lameness and optimise the treatment of aseptic degenerative joint conditions, Audevard Laboratories announce the return of Adequan to the European market.
A targeted action on the cartilage matrix thanks to a unique composition
Managing conditions that cause the degradation of joint components (cartilage structure, synovial fluid) remains a real therapeutic challenge in equine medicine. This degradation leads to a 30 percent decrease in cartilage glycosaminoglycans and a 36 percent decrease in hyaluronic acid.
Adequan’s unique composition acts directly at the heart of the joint. The PSGAG (Polysulfated Glycosaminoglycans) in Adequan are specific glycosaminoglycans enriched with sulfate groups. Their rapid binding within the cartilage inhibits degradation and stimulates the synthesis of hyaluronic acid and proteoglycans – both essential elements for proper joint function.
Fast and long-lasting efficacy
Administration is performed via intramuscular injection: one vial (5ml containing 500mg) every 4 days, for a total of 7 injections, with a zero-day detection time. The molecule penetrates the joint within 2 hours, allowing rapid action on aseptic degenerative joint disease and the associated lameness. In addition to its fast-acting effect, Adequan’s PSGAGs provide long-term management, with proven efficacy on lameness for up to 6 months.
By reintroducing Adequan to the European market, Audevard Laboratories provide equine veterinarians with the only UK equine licensed PSGAG treatment offering targeted action on the cartilage matrix and proving a marked reduction in lameness.
You can find more information on Adequan here.
